<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994301</url>
  </required_header>
  <id_info>
    <org_study_id>FLASK20A0</org_study_id>
    <nct_id>NCT04994301</nct_id>
  </id_info>
  <brief_title>Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients</brief_title>
  <official_title>Lung T1 MRI Assessments of Children With CF Initiating Trikafta Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this observational study, the investigators evaluate the sensitivity of T1-MRI to identify&#xD;
      lung perfusion changes in pediatric patients with CF (age = 6-11) before and after initiating&#xD;
      FDA-approved Trikafta therapy. The investigators compare these Lung T1 MRI assessments (%&#xD;
      Normal lung perfusion) to currently best-available assessments of lung function in CF&#xD;
      patients (i.e., MBW (LCI( and Spirometry (FEV1 % Predicted).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study with 3 study visits to evaluate the utility of Magnetic Resonance&#xD;
      Imaging (MRI) and clinical lung function assessments to detect changes in Cystic Fibrosis&#xD;
      (CF) patients before and after administration of the FDA-approved Trikafta therapy. The 3&#xD;
      study visits include:&#xD;
&#xD;
      Visit 1: Before starting Trikafta Visit 2: 3 months from start of Trikafta Visit 3: 6 months&#xD;
      from start of Trikafta&#xD;
&#xD;
      Along with the clinical assessments (MBW and Spirometry), all participants will undergo an&#xD;
      MRI scan of the lungs to generate quantitative lung T1 maps. The investigators will compare&#xD;
      the lung T1 MRI (% Normal Lung Perfusion) to Multiple Breath Washout (LCI) and spirometry&#xD;
      (FEV1 % Predicted) as methods to assess lung changes with administration of Trikafta. The&#xD;
      investigators will obtain additional clinical assessments from participant's medical records.&#xD;
&#xD;
      This is a multi-site study involving 3 sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung T1-MRI</measure>
    <time_frame>Visit 1: Before starting Trikafta, Visit 2: 3 months (+/- 15 days) from start of Trikafta, Visit 3: 6 months (+/- 30 days) from start of Trikafta</time_frame>
    <description>Evaluate lung T1-MRI (% Normal Lung Perfusion) to assess lung perfusion changes associated with FDA-approved Trikafta therapy in pediatric cystic fibrosis patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>Visit 1: Before starting Trikafta, Visit 2: 3 months (+/- 15 days) from start of Trikafta, Visit 3: 6 months (+/- 30 days) from start of Trikafta</time_frame>
    <description>Clinical standard pulmonary function test (FEV1 % Predicted).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple breath washout (MBW)</measure>
    <time_frame>Visit 1: Before starting Trikafta, Visit 2: 3 months (+/- 15 days) after start of Trikafta, Visit 3: 6 months (+/- 30 days) after start of Trikafta</time_frame>
    <description>Multiple breath washout to assess lung clearance index (LCI) applied per CF clinical standard.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Patient with Cystic Fibrosis</arm_group_label>
    <description>Patients (male, female) age 5-11 with confirmed diagnosis of Cystic Fibrosis. These patients will begin clinically prescribed FDA-approved Trikafta therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lung T1 MRI</intervention_name>
    <description>Evaluation of lung T1 MRI to Assess Lung Disease</description>
    <arm_group_label>Patient with Cystic Fibrosis</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Oropharyngeal swab for the extraction of bacterial DNA only.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cystic fibrosis (CF) who are planning to start Trikafta therapy once approved&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Male or female individuals with a diagnosis of cystic fibrosis and have at least one copy&#xD;
        of the F508del mutation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who cannot hold their breath for up to 15 seconds.&#xD;
&#xD;
          -  Subjects who are pregnant.&#xD;
&#xD;
          -  Subjects with MRI contraindication (e.g., heart pacemaker, heart defibrillator, metal&#xD;
             in within the body.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Flask, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly M MD, PhD, FACP, MD, PhD</last_name>
    <phone>216-844-3267</phone>
    <email>Kimberly.McBennett@UHhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Flask, PhD</last_name>
    <phone>216-844-4963</phone>
    <email>caf@case.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clement Ren, MD, MBA, ATSF</last_name>
      <phone>317-948-7180</phone>
      <email>clren@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CS Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samya Z Nasr, MD</last_name>
      <email>snasr@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly M MD, PhD, FACP, MD, PhD</last_name>
      <phone>216-844-3267</phone>
      <email>Kimberly.McBennett@UHhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Chris Flask, PhD</last_name>
      <phone>216-844-4963</phone>
      <email>caf@case.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Kimberly McBennett, MD, PhD, FACP</investigator_full_name>
    <investigator_title>Director, Adult Cystic Fibrosis Center</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Transmembrane</keyword>
  <keyword>Conductance</keyword>
  <keyword>Regulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Unsure if individual data will need to be presented.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

